CN Mobile Logo


Cancer and Genetics

Cancer and Genetics

In this video we discuss the use of biomarker-guided treatment in phase I trials, which can yield high response rates.

In this video we discuss a large-scale genomic analysis that found that patterns of genetic changes detected in circulating tumor DNA mirror those identified in tumor tissue biopsies.

The FDA has approved the cobas® EGFR Mutation Test v2, the first “liquid biopsy” blood test for detecting EGFR gene mutations in non-small cell lung cancer.

Clinicians now have a new tool to better identify colorectal cancer in its early and more treatable state.

Patients diagnosed with non-small-cell lung cancer (NSCLC) at a younger age are far more likely to harbor a targetable genomic alteration than older patients.

A new study at a single center in Japan found no significant differences in the rate of BRCA mutations between ovarian cancer patients with or without family histories of the mutations and recommends that BRCA1/2 testing be required for all ovarian cancer patients

A new genetic analysis found five new genetic variants that raise the risk for gliomas. One of the five was associated with a sharply increased risk for glioblastoma.


Subscribe to Cancer and Genetics on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.